Antiadrenergic effects of adenosine in pressure overload hypertrophy

T E Meyer1, E S Chung, S Perlini

  • 1Department of Medicine, University of Massachusetts (Worcester), USA. meyert@ummhc.org

Insights

In pressure overload hypertrophy, adenosine

Area of Science:

  • Cardiovascular Physiology
  • Cardiac Metabolism
  • Pharmacology

Background:

  • Pressure overload hypertrophy (POH) is a cardiac condition.
  • Adenosine plays a role in cardiac adrenergic signaling.
  • Altered adenosine signaling may contribute to heart dysfunction.

Purpose of the Study:

  • To investigate adenosine's antiadrenergic effects in POH.
  • To determine if adenosine receptor function is impaired in POH.
  • To assess the impact of adenosine signaling on cardiac contractility and calcium handling in POH.

Main Methods:

  • Rats underwent suprarenal aortic banding to induce POH.
  • Adenosine and inosine levels were measured in epicardial and coronary effluent.
  • Contractile responses to beta-adrenergic stimulation were assessed.
  • Adenosine and selective A(1) and A(2A) receptor agonists/antagonists were used.
  • Isolated myocytes were used to measure intracellular calcium transients.

Main Results:

  • Adenosine and inosine levels increased in compensated POH but decreased in heart failure.
  • Antiadrenergic effects of adenosine were diminished in POH, correlating with dilation and dysfunction.
  • Adenosine's sustained antiadrenergic effect was lost in decompensated hearts.
  • A(2A) receptor antagonism did not restore adenosine sensitivity in hypertrophied hearts.
  • Myocytes from hypertrophied hearts showed impaired suppression of calcium transients.

Conclusions:

  • Myocardial adenosine levels fluctuate during POH progression.
  • Adenosine's antiadrenergic actions via A(1) receptors are reduced in POH.
  • Diminished adenosine signaling may increase vulnerability to sympathetic overactivity in hypertrophied hearts.

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...